Topic: Metformin reduces ICC risk in diabetic patients
Metformin may do double duty in diabetes patients by decreasing their risk of developing certain types of liver cancers in addition to reducing their blood sugar, studies have shown.
Treatment with the glucose-lowering drug was associated with a nearly 60% reduction in the risk of intrahepatic cholangiocarcinoma (ICC) among diabetes patients in one study presented at Digestive Disease Week 2012
What I wonder after reading this article:
If metformin reduces the risk of ICC in diabetic patients, maybe just maybe it can reduce the risk of recurrence in CC patients whose disease is in remission?